Linafexor | m-entrepreneurship.com

Product Name :
Linafexor

Search keywords :
Linafexor

drugId :
null

Target Vo:
Bile acid receptor FXR

Target Vo Short Name :
FXR

Moa_Name:
Bile acid receptor FXR agonists

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences

Active Company_Name :
Cascade Pharmaceuticals Inc

Active Indication_Name:
Liver Cirrhosis, Biliary

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 2 Clinical

China Highest Status:
Phase 2 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Bebtelovimab SARS-CoV
Etigilimab Cancer
CD90/Thy-1 Antibody: CD90/Thy-1 Antibody is an unconjugated, approximately 12 kDa, rabbit-derived, anti-CD90/Thy-1 polyclonal antibody. CD90/Thy-1 Antibody can be used for: WB, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, rat, and predicted: dog, pig, horse, sheep background without labeling.

Author: Betaine hydrochloride

Related Posts